Where did former vaccine regulator Peter Marks find a new job? How did a math error cost AstraZeneca a rare disease candidate? And is biotech back?

We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on Mizuho health care strategist Jared Holz to discuss the rebound in biotech stocks and sentiment.

We also talk about Marks’ new role at Eli Lilly after leaving the Food and Drug Administration, an attempt by a biotech to revive a rare disease drug shelved by AstraZeneca, and new funds raised by China-focused Expedition Therapeutics.

How will we look back on Emma Walmsley's tenure as GSK's CEO? Why did one of the FDA's top drug officials call out an obscure lupus drug on LinkedIn? And will we ever stop talking about the pharma patent cliff?
Adam is out this week, so Allison and Elaine dive into the latest news, starting with another biotech acquisition and a new CEO at GSK. Then, they invite health policy researcher Stacie Dusetzina to break down President Trump's "most-favored nation" pricing deal with Pfizer.

We bring on UniQure CEO Matt Kapusta to discuss the company's announcement this week that its one-time treatment for Huntington’s disease significantly slowed down the neurological condition in a key study.

We also chat about the Trump's administration initiatives on autism. Officials this week warned pregnant women not to take Tylenol, saying that it may cause autism, and they announced an FDA decision to make a decades-old drug called leucovorin available as a treatment for people with certain autism symptoms. To unpack the implications of these statements, we bring on by Ari Ne'eman, an assistant professor of health policy and management at Harvard’s school of public health who researches how policies affect people with disabilities.

STAT's European correspondent Andrew Joseph calls in from the U.K. to the podcast to dissect why companies like Merck and GSK are putting their money elsewhere.

We also discuss the Advisory Committee on Immunization Practices, or ACIP, meeting and biotech M&A, including Roche's $3.5 billion acquisition of 89bio and its MASH drug, announced this week.

Listeners of this podcast probably know pharma consultant Mike Rea for his annual ranking of drug company R&D productivity. But this week, he penned a poignant personal essay explaining how some medical setbacks have impacted his professional life. He joins us to discuss.

But first, President Trump is considering a significant crackdown on drugs invented in China, according to a recent report in the New York Times. Industry support for the possible measures are mixed, however. While strengthening the U.S. biopharma industry garners wide support, so too does the freedom to source innovative drugs from Chinese biotechs.

Labor Day is in the rearview mirror, and that means Adam, Elaine, and Allison are all back to work. They take the pulse of the biotech market and discuss forthcoming data readouts at two sleep and lung disorder conferences. But first, they discuss the bubbling uncertainty in the vaccine field.

We bring on Washington correspondent Chelsea Cirruzzo to explain the ouster of CDC Cirector Susan Monarez and the resignations of other top officials.

We also chat about STAT's annual VC rankings report, as well as ongoing issues at a major drug manufacturing site that was owned by Catalent and now owned by Novo Nordisk.

On this week’s episode of “The Readout LOUD”: vikings. No, not the seafaring Norse people of the 10th century, or the Minnesota football team. The gang will discuss obesity drug developer Viking Therapeutics and the investor cult that embraces it, both of which performed a painful belly flop this week.

Then, we’ll dish on the growing “pharm to table” movement. That’s the clever buzzphrase bandied around by Big Pharma insiders to promote plans that sell drugs directly to consumers — supposedly at lower costs that will make President Trump happy. Except as our cohost Elaine Chen reported this week, these direct-to-consumer plans championed by Eli Lilly, Novo Nordisk, Bristol Myers Squibb, and others are unlikely to make drugs more affordable. We’ll dig into the details.

We discuss the sudden return of Prasad and the mixed prospects for mRNA. Then, we invite STAT fellow Marissa Russo on to discuss the alternatives to animal testing, and why they’re the subject of hot debate among scientists.

We bring on Natalie Holles, who was the CEO of Third Harmonic Bio, which recently decided to dissolve and return cash to shareholders. She walks us through why the company has decided to do this and her advice for other biotech CEOs.

We also chat about a disappointing readout from Eli Lilly's key small molecule GLP-1 candidate, setbacks in Vertex's pain business, and the story behind Replimmune's recent FDA rejection.